Searched for
EISAI CO LTD
Eli Lilly's Alzheimer's drug donanemab approved in India, but neurologists flag cost, access barriersA new drug for Alzheimer's, donanemab, has arrived in India. It aims to slow the disease's progression by clearing brain plaques. While off...- Nikkei closes above 33,000 for the first time in 33 yearsThe Nikkei rose by 1.8% to close above 30,000 for the first time in 33 years led by tech shares, including SoftBank Group and Advantest Cor...
- New Alzheimer drug 'lecanemab' by Eisai Co and Biogen shows positive results but......, read what study saysThe ‘Eisai’ and ‘Biogen’ drug slowed cognitive decline in study participants, but many experienced brain bleeds, swelling, or other side ef...
- Biogen appoints ex-Sinofi boss Christopher Viehbacher as its next CEO. Here are the detailsAfter a month gap in choosing the new CEO after Michel Vounatsos, Biogen has finally named Christopher Viehbacher as its new CEO.
- Lecanemab: All about the Alzheimer's drug that shows promiseClinical trials on 1800 patients with early-stage Alzheimer's has showed that Lecanemab slows the advance of the disease.
- At last, a drug to slow down Alzheimer'sEisai Co, a Tokyo-based pharmaceutical company with a family bent and market capitalisation of $14 billion, crossed the finish line before ...
- Dr Reddy's inks pact with Citius Pharma to sell all rights to anti-cancer agent E7777Dr Reddy's will receive $ 40 million upfront upon the closing of the transaction, followed by approval milestone payment of up to $40 milli...
- Nikkei slips 0.3% at close; Japan shares end lower on caution ahead of US inflation dataThe Nikkei share average ended 0.35 per cent lower at 28,860.80, while the broader Topix was down 0.28 per cent at 1,957.14.
- Heavyweights pull Nikkei lower, Topix gains on drugmakers' boostNikkei inched down 0.2 per cent to close at 28,963.56, while the Topix edged up 0.1 per cent at 1,962.65.
- Japan shares hit 5-week high on vaccine, economic growth hopesThe Nikkei index settled 1.59% higher at 22,945.50 after hitting its highest level since June 10, with industrial and consumer discretional...
- Japanese shares rebound but spike in COVID-19 cases caps gainsSony Corp added 3.27%, while Yaskawa Electric Corp rose 1.98%.
- Japanese shares snap 3-day losing streak as battered stocks bought backThe Nikkei share average rose 1.52 per cent to 19,429.44 after three straight sessions of losses.
- Nikkei closes flat even as chip makers make a buzzChip equipment makers jumped, tracking a rise in US tech shares overnight.
- Nikkei rises to 2-week high on weak yen, pharmaceuticalsThe weaker yen triggered futures buying in late trade.
- Japanese companies make cautious return to Indian pharma marketOther drug companies whose acquisition went southwards included Mitsui & Co, which acquired a significant stake in Arch Pharma.
- Dr Reddy's launches Alzheimer's disease drug in US marketDr Reddy's Laboratories today said it has launched generic Donepezil Hydrochloride tablets, used to treat Alzheimer's disease, in the US ma...
- Ranbaxy gets US FDA approval to sell Alzheimer's disease drugRanbaxy Laboratories on Tuesday said it has received approval from the US health regulator to sell generic Alzheimer's disease drug donepez...
- Telengana unrest takes a heavy toll on pharma industry in APPharma companies in Andhra Pradesh say they are losing heavily due to the Telengana unrest in the State.
- Ranbaxy gets USFDA nod to mkt generic copy of AriceptRanbaxy Laboratories has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture and market donepezil h...
- Japanese drug major Eisai plans production in IndiaJapanese drug major Eisai Company, which has a marginal presence in India with just two products, will soon invest Rs 180 crore to start ma...
Load More
